You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦制藥(03933.HK)擬折讓7.9%配售1.56億股 總籌22億港元加碼研發與產能
格隆匯 07-18 08:32

格隆匯7月18日丨聯邦制藥(03933.HK)發佈公吿,2025年7月18日(聯交所交易時段前),公司與獨家配售代理(即瑞銀集團)訂立《配售協議》,據此,公司已經同意委聘獨家配售代理、而獨家配售代理亦同意接受委聘,以盡力促使買家按配售股份每股14.16港元的配售價,認購最多1.56億股配售股份。該等配售股份將根據一般授權配發及發行。

配售股份1.56億股,相當於:(a)公司截至本公吿日期的已發行股本總數的約8.59%;及(b)完成配發及發行配售股份後的已擴大的已發行股本總數的約7.91%。配售股份每股配售價14.16港元,較:(a)股份在最後交易日在聯交所所報收市價每股15.380港元折讓約7.93%。

假設配售項目得以完成並且配售股份獲全數配售,募集所得總額約22.09億港元,估計(在扣除相關開支費用後)所得淨額約21.682億港元。按此基礎,配售股份每股淨價約13.90港元。公司擬將配售項目所得款項淨額中約13.009億港元用作建設和擴充生產設施、加強外部合作、擴展國際業務及其他一般公司用途的資本開支,所得款項淨額中約8.673億港元用於創新候選產品的研發,包括UBT251的臨牀試驗,以及其他開發中產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account